Publications by authors named "Laurel Adams"

Claim this Profile
E
Evaluation of Barriers and Interventions for Emergency Department-Initiated Naltrexone for the Treatment of Alcohol Use Disorder.
Ivan Covarrubias, Hannah Dart, Laurel Adams, Jeffrey Calvin Moon, Samantha Huo

J Emerg Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
Pamela Munster, Rahul Aggarwal, David Hong, Jan H M Schellens, Ruud van der Noll, Laurel Adams

Clin Cancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Geoffrey I Shapiro, Stewart McCallum, Laurel M Adams, Laurie Sherman, Steve Weller

Invest New Drugs· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
Rajendra P Singh, Bela Patel, Howard Kallender, Lone H Ottesen, Laurel M Adams

J Clin Pharmacol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients.
Laurel M Adams, Brendan Johnson, Sharon Murray

Clin Pharmacol Drug Dev· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Joanne Brady, Pippa Corrie, Ian Chau, Raghunadharao Digumarti, Laurel M Adams

Invest New Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Geoffrey I Shapiro, Stewart McCallum, Laurel M Adams, Laurie Sherman, Steve Weller

Invest New Drugs· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and evaluation of the activities measure for upper limb amputees.
Linda Resnik, Laurel Adams, Matthew Borgia, Jemy Delikat, Roxanne Disla

Arch Phys Med Rehabil· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, Theodore F Logan, Andrea L Harzstark, Laurel M Adams

J Clin Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Elisabeth I Heath, Karen Forman, Lisa Malburg, Shelby Gainer, A Benjamin Suttle, Laurel Adams

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
John W Bauman, Joyce M Antal, Laurel M Adams, Brendan M Johnson, Sharon C Murray

Invest New Drugs· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
Aung Naing, Razelle Kurzrock, Laurel M Adams, Joseph F Kleha, Kevin H Laubscher

Invest New Drugs· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer.
Uday B Dandamudi, Laurel M Adams, Brendan Johnson, John Bauman, Shannon Morris

Cancer Chemother Pharmacol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine.
Stefano Zamuner, Brendan M Johnson, Sabrina Pagliarusco, Paolo Fina, Michela Peroni, Laurel M Adams

Br J Clin Pharmacol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Brendan M Johnson, Laurel M Adams, Ke Zhang, Shelby D Gainer, Lyndon C Kirby

J Clin Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
Lyndon C Kirby, Brendan M Johnson, Laurel M Adams, Derek J Eberwein, Ke Zhang

J Clin Pharmacol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
Laurel M Adams, Brendan Johnson, Ke Zhang, Lin Yue, Lyndon C Kirby

Support Care Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Brendan Johnson, Laurel Adams, Emily Lu, Ke Zhang, Peter Lebowitz

Support Care Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.
Chooi P Lee, Maja J A de Jonge, Anne E O'Donnell, Kristel L Schothorst, Janet Hanwell, Laurel M Adams

Clin Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis